C4 Therapeutics (CCCC) Share-based Compensation (2019 - 2026)

C4 Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 51.5% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $16.3 million, a 43.83% decrease from a year earlier, with the FY2025 full-year figure at $19.1 million, down 35.61% from the prior year.
• Share-based Compensation fell to $2.7 million in Q1 2026 per CCCC's latest filing, from $4.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $44.1 million in Q1 2022 and bottomed at -$27.0 million in Q2 2022.
• The 5-year median for Share-based Compensation is $6.3 million (2023), against an average of $7.2 million.
• Biggest YoY gain for Share-based Compensation was 1046.09% in 2022; the steepest drop was 616.09% in 2022.
• Year by year, Share-based Compensation stood at $21.0 million in 2022, then slumped by 69.68% to $6.4 million in 2023, then rose by 29.5% to $8.2 million in 2024, then sank by 51.34% to $4.0 million in 2025, then tumbled by 33.34% to $2.7 million in 2026.
• Per Business Quant, the three latest CCCC Share-based Compensation figures stand at $2.7 million (Q1 2026), $4.0 million (Q4 2025), and $4.6 million (Q3 2025).